Cancer Patient Experience

John Baron Excerpts

Wednesday 30th October 2013 Westminster Hall

[Mr Clappison]

I am grateful to the hon. Gentleman for that intervention. I agree that communication skills are important; the important factor is that kindness should be received by the patient.

I put a point to the Minister on behalf of Macmillan Cancer Support: I hope that the Government will deal with the matters we have discussed and put patient experience at the heart of the inspection process being put in place for our health service. One way of doing that is to use the results of the cancer patient experience survey to inform ratings at a cancer team and service level and to monitor and assess providers of care—for example, as part of the foundation trust assessment process.

In the light of all that, I have four specific questions for the Minister, on behalf of Macmillan Cancer Support and other charities. First, will the Government consider making relational care a priority area in the refreshed 2014-15 mandate to NHS England? Secondly, will the Government support the use of cancer patient experience data in the inspection regime of the Care Quality Commission, which is led by the chief inspector of hospitals?

Thirdly, will the Government work with commissioners and providers to ensure that the results of the national cancer experience survey continue to drive improvements in cancer care? Fourthly, and specifically on breast cancer, can the national cancer patient experience survey include a question asking whether the respondent has secondary breast cancer? The Breast Cancer Campaign specifically asks to have that included.

More generally, I welcome the Government’s ambitious plans to improve cancer care in the United Kingdom, including those they set out in January 2011 in “Improving Outcomes: A Strategy for Cancer”, which promised action on a number of important fronts, such as diagnosing symptomatic cancer earlier; helping people live healthier lives to reduce the incidence of preventable cancers; screening more people; introducing new screening programmes, as recommended by the National Screening Committee; and ensuring that all patients have access to the best possible treatment, care and support.

Those measures should save at least an additional 50,000 lives every year by 2014-15. Many of us will be aware of the efforts being put into those different fields, to encourage people to come forward for screening, to make screening available, to make members of the public more aware of symptoms and to encourage people to lead healthier lives. That has been much more evident than it had been hitherto. In the light of all that, it would be good to hear from the Minister what progress has been made on the ambitions that the Government set out in January 2011.

Furthermore, what progress has been made in tackling inappropriate regional variations in cancer outcomes? Many advances have been made in cancer treatment in the UK, of course, but historically there has been a disparity on cancer survival rates between the UK and other comparable western nations. That has been the case for many years, under Governments of all parties, but it was underlined most recently by a 2009 Eurocare study, which revealed a disparity between UK cancer survival rates and those achieved in countries with the best outcomes.

England rated 16th in the survey for both men and women. Wales was ranked just in front, and Scotland and Northern Ireland were just behind. Apart from Ireland, every other major western European nation performed better than the UK, and some of them much better. Sweden was the best performing country.

The 2009 analysis was a little old, because it was based on patients diagnosed between 1995 and 1999, although that had to be the case to detect survival rates. More recent surveys have also seen the same pattern, such as one comparing the USA with the United Kingdom. With older patients, there is an even more marked gap between the UK and other comparable nations and economies. I have seen figures from the British Journal of Cancer that show that for women over 70 with breast cancer, the three-year survival rate in the UK is 79%, but in Sweden, it is 91%.

[Mr John Baron (Basildon and Billericay) (Con)]

I congratulate my hon. Friend on securing the debate. Although comparisons are always dangerous, a further acknowledgement of how far we remain behind our European partners is that even if we met the Government’s laudable target of saving an extra 5,000 cancer lives over the next couple of years, that would still only bring us up to the European average on survival rates.

[Mr Clappison]

My hon. Friend makes an excellent point. I am sure he would agree that there is a lot of ground to make up. The important point is that we should not only take encouragement from the improvement of survival rates as a result of advances in medical science; we should judge ourselves by how well we use those advances compared with other countries. We should set ourselves the more ambitious target of not just improving survival rates, but improving them so much that we close the gap on other countries.

Members of the British public who fall ill with cancer and their families expect cancer treatment to be on a level with that of comparable countries, our neighbours and other western developed economies. Sadly, it is not at that level, although I hope the Minister will tell us that we have made some progress.

Yesterday, some encouraging statistics were released that showed a trend of increasing survival for patients diagnosed between 2007 and 2011. The Minister will agree that that is good news, but I look forward to hearing from her that the Government’s ambition is to close the performance gap between ourselves and other countries and that the gap is being closed.

In closing, I should like to pay the utmost respect to doctors, nurses and all clinicians working in the field. We owe them a great debt of gratitude and my comments are no reflection on them. We are all hugely indebted to their work and I am sure that many of our constituents would echo that sentiment. I am just drawing attention to how the system has operated in this country over a number of years, and the experience of the patients within it. I hope that the Minister can tell me that the Government have ambitious plans for improving the cancer patient experience and that there is evidence that those plans are on the road to fulfilment.

--- Later in debate ---

[Mr John Baron (Basildon and Billericay) (Con)]

I congratulate my hon. Friend the Member for Hertsmere (Mr Clappison) on securing this important debate. I apologise to him that I will have to leave slightly early to meet, coincidentally, the new cancer tsar, Mr Sean Duffy. That appointment has been in the diary for some time. I echo my hon. Friend’s warm words of praise for all those charities and individuals who work towards combating this disease. They do excellent work, which I know all of us across the House very much support and praise.

As chairman of the all-party group on cancer, I congratulate the Government on their excellent work on cancer in recent years. Focusing on outcomes as a driver of change within the NHS has been crucial in not only driving up outcomes, but ensuring that changes in the NHS take place for the benefit of patients.

I will not speak for long, because I am conscious that there will be other speakers after me, but to give a little bit of the history, the all-party group produced a report in 2009 on cancer inequalities across the UK. We tried to analyse why patients who reach the one-year point in this country stood as much chance of getting to the five-year point as in any other health system in Europe, while we fell down on getting patients to the one-year point. That result tends to suggest that the NHS is as good as, if not better, at treating patients once cancer has been diagnosed, but is very poor at diagnosing cancer in the first place.

We tried to come up with a solution for how to drive forward earlier diagnosis. I suggest that that is the magic key for cancer. There are very few magic keys in life that will unlock the door to a panoply of unexpected treasures, but one exists for cancer—earlier diagnosis. With the wider cancer community, the all-party group—it sees itself as representing that community in Parliament—proposed putting up in lights the one-year and five-year survival indicators.

Instead of bombarding local primary care trusts, as they then were, with lots of targets and bureaucracy, we decided to put up those indicators in lights, with the emphasis on the one-year point, as a driver of change. PCTs—now clinical commissioning groups—that were towards the bottom of the table would, if their managers were worth their salt and their large salaries, introduce local initiatives, peculiar to their population: for example, whether theirs was an ageing population, whether an adaptation was needed for an industrial illness, such as mesothelioma, or whether there were black and minority ethnic communities. Those local initiatives would drive up earlier diagnosis to combat those poor one-year survival figures, because we all know that late diagnosis makes for poor one-year survival figures and, in turn, poor five-year figures.

The Government listened not only to us, but to the cancer community that also came up with the idea, and to Members from both sides of the House who came in behind it. We campaigned together, and we are delighted that the Government have now put in place one-year and five-year survival figures both nationally and locally through the CCG outcomes indicator set—brilliant news.

There has to be a bit of tweaking, for the simple reason that we were previously dealing with PCT populations that were larger than those of CCGs, so the issue of statistical significance comes into play. I was not wholeheartedly behind—in fact, if anything, I was quite sceptical—about the structural changes to the NHS, but that is now history and we have to deal with the future. Given that the populations are smaller, we are now arguing for the introduction of proxy measures locally to supplement, although not to replace, the one-year figures. Measures focusing on accident and emergency and on staging would be two ways to supplement the one-year figure. That is an ongoing conversation, and the Government and NHS England are in constructive dialogue with us about it.

I mentioned the focus on outcomes because, to achieve improved cancer outcomes, it is essential to put up in lights the patient experience and to prioritise it nationally and locally. If I have one concern about the present direction of Government policy, it is that patient experience is built in at national level, through the outcomes framework, but as yet, it is not built in at the local or outcomes indicator set level. I am not alone in worrying that there will be a disconnect. Setting the bigger picture strategy is well intentioned and essential, but if we are really to improve patient experience, we need to ensure that that national policy is followed through locally. At the moment, that is not taking place, and if we do not put that right pretty quickly, we risk not meeting the Government’s laudable target of an extra 5,000 lives saved by 2015, which is something that we all very much want.

The Minister, to whom I wish the very best in her new post—I did not get the opportunity to say that in Health questions—will know from her civil servants that the cancer community and the APPG on cancer participated in the public consultation on the 2013-14 clinical commissioning group outcomes indicator set. Held by the National Institute for Health and Care Excellence, it listed patient experience of cancer services as a potential indicator for future development. The NICE CCG OIS advisory committee agreed that such experience would be useful, yet it is not included in the 2014-15 CCG outcomes indicator set. I ask the Minister in all earnestness to look at that again. We are talking about NHS England to a very large extent, but I would be very surprised if there were not conversations with it about such issues. Will the Minister use her influence and best offices to try to influence the debate?

There is no shortage of reasons why cancer patient experience is important and why it should be included locally. I will bombard the Minister with one or two facts. We know, for example, that there is vast variation of cancer care across the country. There are unacceptable geographical variations, and we need to iron them out. There have been some particularly bad examples recently in London, and we need to look at them.

Within cancer itself and the condition of cancer, there are huge variations. For example, people with rarer cancers report a worse experience. People in the most deprived areas report less favourably on their care. Those are reasons why the monitoring of cancer patient experience locally is important.

Furthermore, the cancer patient experience survey is effective at driving improvements locally, and that must not be overlooked. By contrast to the current CCG OIS indicators under domain 4, the cancer patient experience survey captures detailed service specific data about trusts’ performance across a range of aspects of cancer patient experience. For example, all London trusts put action plans in place, following the 2010 cancer patient experience survey, so we know that that is effective. We do not need to reinvent the wheel on that one; we have something within our possession that is effective in driving forward improvements. The idea of monitoring cancer patient experience locally is feasible.

As my hon. Friend the Member for Hertsmere mentioned, more than 2 million people are living with and beyond cancer. That will rise to 4 million by 2030. Cancer is a unique and complex medical condition, and as we well know, certain aspects of patient experience have a particular emphasis for people living with cancer.

The CPES has a high sample size and response rate. Data from the 2010, 2011 and 2012 surveys are already easily accessible for CCGs to analyse. They are useful and user friendly. Furthermore, the CPES is regarded as an example of best practice in measuring holistic patient experience of care—looking at the complete pathway—which is something that we do not talk enough about in the NHS. It is particularly important, as the Minister fully understands, when it comes to cancer patients.

In conclusion, lots of good work is being undertaken by the Government on cancer. The Minister will know that I am not afraid to come forward and say otherwise if I think that that is the case. None the less, I urge her to look again at what appears to be a disconnect between a national priority and implementation locally. The cancer patient experience survey is terribly useful, helpful and effective. We need to get it into the CCG OIS. I hope the Minister will respond to that point when she sums up, but I apologise that I will not be here to listen to her.